A systematic review of the safety and efficacy of monoclonal antibodies for progressive multiple sclerosis

CONCLUSION: Based on our findings, Ocrelizumab is the most efficient monoclonal antibody for primary PMS, although it is associated with a higher risk of infection. While other monoclonal antibodies did not show significant promise in treating PMS, more research is necessary.PMID:37209514 | DOI:10.1016/j.intimp.2023.110266

Source: International Immunopharmacology - May 20, 2023 Category: Allergy & Immunology Authors: Zahra Sabahi Amin Daei Sorkhabi Aila Sarkesh Amirreza Naseri Nazli Asghar-Rezaei Mahnaz Talebi Source Type: research